Navigation Links
Minimally Invasive Heart Valve Therapy Improves Heart Function, Quality of Life for Mitral Regurgitation Patients
Date:3/14/2010

EVANSTON, Ill., March 14 /PRNewswire/ -- NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented data today at the American College of Cardiology annual scientific sessions from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy) demonstrating the MitraClip, a novel, first-in-class catheter-based device,  is a safe and effective alternative to open heart surgery for select patients with mitral regurgitation.

"This is a major advancement in cardiac care," said Ted Feldman, MD, principal investigator of the trial and director of NorthShore's Cardiac Catheterization Laboratory where he became the first physician in the U.S. to use any method for non-surgical repair of leaking mitral valves. "It's the first catheter-based therapy for a mitral valve problem to complete a trial, and has transformed the lives of patients suffering from moderate to severe mitral regurgitation."

Over eight million people in the US and Europe have Mitral Regurgitation (MR), a condition in which the mitral valve leaflets do not seal tightly. This valvular defect allows blood to flow backward into the heart and is often referred to as a "leaking heart valve". The condition can cause shortness of breath, fatigue, coughing, heart palpitations, swollen feet or ankles and heart murmur.  If left untreated, MR's progressive nature could lead to heart failure, stroke, heart attack or death.  The MitraClip is designed to help these patients on a case-by-case basis, and is currently under review by the FDA.

Patients participating in the EVEREST II trial experienced improvements in heart function, quality of life and the ability to engage in normal physical activity.  "[Before the procedure] I had a hard time walking up the stairs. I would have to stop several times and sometimes sit down to catch my breath," said Beyna, an EVEREST II trial participant and NorthShore patient.  "Now it's different. I don't get out of breath and I can do the things I couldn't do before."

In Phase I of the trial, started in 2003, 107 patients had their mitral valves repaired with the MitraClip, a 4 mm-wide, polyester-covered device developed by Abbott Vascular, Inc. Under general anesthesia, the clip (or sometimes two) is inserted via catheter through an artery in the groin, threaded up to the heart and clamped to the mitral valve's two edges to hold them together. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine.

The results of Phase II, announced today, are very promising. A one-year follow-up showed that only 9.6 percent of the 279 MitraClip patients had safety issues associated with the procedure vs. 57 percent of open-heart patients. In terms of effectiveness, 72.4 percent of MitraClip patients had successful reduction of MR vs. 87.8 of surgical patients. Importantly, patients treated with the MitraClip could still have traditional surgery if needed.  

About the EVEREST II Trial

The EVEREST II pivotal trial is a multi-center, randomized clinical trial of 279 patients with moderate-to-severe (3+) or severe (4+) mitral regurgitation who were candidates for mitral valve surgery. The mean age for patients was 68 years, and patients in the trial tended to have more co-morbidities, such as hypertension and congestive heart failure, than the average surgical patient as defined by the 2008 Society for Thoracic Surgery (STS) Database. Patients had at least moderate-to-severe functional or degenerative mitral regurgitation and were either symptomatic or asymptomatic with evidence of compromised left ventricular function, atrial fibrillation, or pulmonary hypertension. The echocardiography core laboratory at the University of California, San Francisco (UCSF) reviewed the trial's echocardiograms based on the American Society of Echocardiography (ASE) criteria for assessment of MR and left ventricular function.

About NorthShore University HealthSystem

Headquartered in Evanston, NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the Chicago Region.  The system includes four hospitals in Evanston, Glenview (Glenbrook Hospital), Highland Park and Skokie.  Further, NorthShore supports teaching and research as the principal teaching affiliate for the University of Chicago Pritzker School of Medicine.  The NorthShore Research Institute focuses on clinical and translational research, including leadership in outcomes research and clinical trials.  The NorthShore University HealthSystem Foundation is a leading philanthropic entity of NorthShore.  It raises charitable contributions, engages volunteer friends and invests in community partnerships.

SOURCE NorthShore University HealthSystem

Back to top
'/>"/>
SOURCE NorthShore University HealthSystem
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. New Minimally Invasive Breast Reconstructive Procedure for Breast Cancer Patients - Actively Recruiting Participants for Clinical Study
3. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
4. Positive Results Published Using AtriCure Minimally Invasive Products
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
7. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
8. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
9. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
10. Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):